Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
IPO Year:
Exchange: NASDAQ
Website: portagebiotech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $26.00 | Outperform | Oppenheimer |
| 3/7/2022 | $32.00 | Buy | HC Wainwright & Co. |
| 9/21/2021 | $30.00 | Outperform | Oppenheimer |
| 9/2/2021 | $40.00 | Buy | B. Riley Securities |
| 8/19/2021 | $35.00 | Overweight | Cantor Fitzgerald |